DEA Rescheduling Bet May Collapse on THCA Hemp Loophole Enforcement Gap

The Unwritten Rules Behind Schedule III

DEA's proposed Schedule III rule doesn't specify whether state and federal compliance testing will measure delta-9 THC or total THC post-decarboxylation. That omission matters. Under current law, hemp is defined by the 2018 Farm Bill as cannabis containing no more than 0.3% delta-9 THC on a dry-weight basis. THCA—the non-intoxicating acidic precursor that converts to delta-9 when heated—doesn't count toward that ceiling.

Rescheduling to Schedule III doesn't repeal the Farm Bill. It doesn't redefine hemp. Unless DEA or Congress explicitly rewrites the testing standard to measure total THC, products with 20% THCA and 0.2% delta-9 remain federally legal hemp, even after rescheduling.

Multi-state operators (MSOs) and hemp-derived cannabinoid producers are now quietly modeling that gap. The math is brutal. If rescheduling doesn't close the THCA loophole, licensed cannabis faces indefinite price competition from unregulated hemp-derived products sold in gas stations, vape shops, and online storefronts.

What MSOs Wagered on Rescheduling

The industry's Schedule III thesis rests on three assumptions: 280E tax relief, interstate commerce for licensed operators, and the end of the hemp-derived cannabinoid gray market. The first two are real. Section 280E prohibits business-expense deductions for Schedule I and II substances; moving cannabis to Schedule III would restore ordinary tax treatment for state-licensed operators, unlocking billions in deductions.

Interstate commerce is murkier. DEA hasn't clarified whether Schedule III cannabis can cross state lines, even between licensed facilities. But the third assumption—that rescheduling kills the THCA loophole—has no regulatory foundation. DEA's May 2024 notice of proposed rulemaking (NPRM) is silent on testing methodology. The agency hasn't proposed amending 21 CFR Part 1308 to replace delta-9 measurements with total-THC calculations.

Why the Loophole Persists

Closing the THCA loophole requires either a new Farm Bill or a DEA rule explicitly redefining hemp to include total THC post-decarboxylation. Neither has happened. The 2018 Farm Bill's 0.3% delta-9 standard was a political compromise, not a chemistry-based threshold. THCA wasn't on lawmakers' radar—most assumed "hemp" meant CBD-rich, non-intoxicating cultivars.

The chemistry changed faster than the law. Breeders developed high-THCA strains that comply with the 0.3% delta-9 limit pre-decarboxylation but convert to 15-25% delta-9 THC when smoked or vaped. Those products—sold as "hemp flower," THCA vapes, and THCA edibles—now account for an estimated $2-4 billion in annual sales, according to industry surveys.

DEA could close the loophole by rule, but doing so would require a separate rulemaking under the Administrative Procedure Act, including public comment and OMB review. That process takes 12-18 months minimum. The Schedule III rule, even if finalized this year, doesn't include that language.

Enforcement Will Vary Wildly by State

State regulators are split on how to handle THCA hemp post-rescheduling. California's Department of Cannabis Control (DCC) already treats THCA as cannabis, requiring total-THC testing for all products. New York's Office of Cannabis Management (OCM) has signaled it'll do the same once rescheduling is final. Texas, Florida, and Ohio—three of the largest hemp markets—haven't updated their testing rules. In those states, THCA hemp remains legal under the Farm Bill's delta-9 standard.

That patchwork creates a compliance nightmare. An MSO operating in California and Florida must work through two conflicting definitions of "hemp." A product legal in Florida could be a Schedule III violation in California, even though both states are bound by the same federal rescheduling order. Enforcement will be inconsistent. The loophole will stay open in permissive states until Congress or DEA acts.

What to Watch Next

The next signal is whether DEA's final Schedule III rule includes a total-THC testing mandate or punts the issue to a future rulemaking. If the agency punts, the THCA loophole survives rescheduling. If it doesn't, MSOs win the regulatory arbitrage they've been betting on. But the odds are long: DEA's NPRM comment period closed in July 2024, and no draft language on testing methodology has surfaced.

For context on the broader rescheduling process, see the CannIntel topic hub on DEA rescheduling.

This is unsettled law. Until DEA or Congress rewrites the testing standard, expect the THCA hemp market to grow—and licensed operators to keep losing margin to unregulated competitors. The rescheduling bet may pay off on taxes, but the loophole math hasn't changed.